Document is current
Any future updates will be listed below
-
Authors
Weber, Alexander N. R. https://orcid.org/0000-0002-8627-7056
McManus, Róisín M. https://orcid.org/0000-0002-6896-0302
Hornung, Veit https://orcid.org/0000-0002-4150-194X
Geyer, Matthias https://orcid.org/0000-0002-7718-5002
Kuemmerle-Deschner, Jasmin B.
Latz, Eicke https://orcid.org/0000-0003-1488-5666
-
Funding
Funding for this research was provided by:
Leibniz-Gemeinschaft
Deutsche Forschungsgemeinschaft (EXC2180, EXC2124, EXC2151)
University of Tübingen | Medizinischen Fakultät, Eberhard Karls Universität Tübingen
Deutsches Zentrum für Neurodegenerative Erkrankungen
Ludwig-Maximilians-Universität München
- License Information
-
More Information
Article History
Received: 26 March 2025
Accepted: 11 June 2025
First Online: 18 August 2025
Competing interests
: E.L. and M.G. are scientific cofounders of IFM Therapeutics, which has developed NLRP3 modulators. A.N.R.W. and J.B.K.-D. have received research grants from IFM Therapeutics and Novartis that funded aspects of research related to NLRP3. None of the funders had a role in conceptualization, information analysis, writing or preparation of the manuscript. R.M.M. and V.H. declare no competing interests.
